Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes
Study Details
Study Description
Brief Summary
Recent studies show that many Type 1 diabetes patients have remaining endogenous insulin production, albeit at low levels. Finding means to increase this production would be of tremendous interest, since residual C-peptide concentrations >0.1 nmol/l previously have been shown to markedly lower HbA1c, decrease blood glucose fluctuations and diminish the risk of ketoacidosis. It also substantially reduces the risks of severe hypoglycemic events and late complications. Liraglutide may through its incretin effect directly potentiate beta-cell function, but also holds the potential to be mitogenic for these cells.
The hypothesis of the present trial is that treatment with liraglutide will not only have a direct effect on beta-cell function, which is more or less immediately observed, but also progressively improve C-peptide concentrations over time.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Liraglutide treatment Liraglutide treatment in the dose of 1.8 mg daily for 52 weeks |
Drug: Liraglutide
Treatment with liraglutide for 52 weeks
|
| Placebo Comparator: Placebo treatment Treatment with placebo once daily for 52 weeks |
Drug: Placebo for liraglutide
Placebo for liraglutide. Treatment once daily for 52 weeks
|
Outcome Measures
Primary Outcome Measures
- The effect of 52 weeks of treatment with liraglutide 1.8 mg/day, compared to placebo, on stimulated C-peptide concentrations in patients with long-standing type 1 diabetes and residual insulin production [52 weeks]
The Area Under the Curve (AUC) change in plasma C-peptide concentration in response to a standardized mixed meal tolerance test (MMTT) during one year of liraglutide treatment (1.8 mg/day)
Secondary Outcome Measures
- Change in C-peptide between 6 and 52 weeks of study [52 weeks]
∆- change in C-peptide AUC between the MMTT after one year and that after 6 weeks of treatment
- Change in C-peptide between after and prior to treatment with liraglutide 1.8 mg [52 weeks]
∆-change in C-peptide AUC between the MMTT three months after cessation of treatment and that after the run-in period
- Change in HbA1c between before and at end of liraglutide (1.8 mg) treatment [52 weeks]
∆- change in HbA1c between after one year and after the run-in period.
- Change in HbA1c between 6 and 52 weeks of study [52 weeks]
∆- change in HbA1c between after one year and after 6 weeks of treatment
- Change in HbA1c between after and prior to treatment with liraglutide 1.8 mg [52 weeks]
∆- change in HbA1c between three months after the cessation of treatment and after the run-in period.
- Change in insulin doses between before and at end of liraglutide (1.8 mg) treatment [52 weeks]
∆- change in exogenous insulin doses between after one year and after the run-in period.
- Change in insulin doses between 6 and 52 weeks of study [52 weeks]
∆- change in exogenous insulin doses between after one year and after 6 weeks of treatment
- Change in insulin doses between after and prior to treatment with liraglutide 1.8 mg [52 weeks]
∆- change in exogenous insulin doses between three months after the cessation of treatment and after the run-in period.
- Change in glucose variability between before and at end of liraglutide (1.8 mg) treatment [52 weeks]
∆- change in glucose variability between after one year and after the run-in period.
- Change in glucose variability between 6 and 52 weeks of study [52 weeks]
∆- change in glucose variability between after one year and after 6 weeks of treatment
- Change in glucose variability between after and prior to treatment with liraglutide 1.8 mg [52 weeks]
∆- change in glucose variability between three months after the cessation of treatment and after the run-in period.
- Change in hypoglycemia frequency between before and at end of liraglutide (1.8 mg) treatment [52 weeks]
∆- change in hypoglycemia frequency (measured plasma glucose levels < 3 mmol/l or assisted hypoglycemia during a one week period) between one year and after the run-in period.
- Change in hypoglycemia frequency between 6 and 52 weeks of study [52 weeks]
∆- change in hypoglycemia frequency (measured plasma glucose levels < 3 mmol/l or assisted hypoglycemia during a one week period) after one year and after 6 weeks of treatment
- Change in hypoglycemia frequency between after and prior to treatment with liraglutide 1.8 mg [52 weeks]
∆- change in hypoglycemia frequency (measured plasma glucose levels < 3 mmol/l or assisted hypoglycemia during a one week period) between three months after the cessation of treatment and after the run-in period.
- Change in Quality of Life (QoL) between before and at end of liraglutide (1.8 mg) [52 weeks]
∆- change in assessment of QoL between after one year and after the run-in period.
- Change in QoL between 6 and 52 weeks of study [52 weeks]
∆- change in assessment of QoL between after one year and after 6 weeks of treatment
- Change in QoL between after and prior to treatment with liraglutide [52 weeks]
∆- change in assessment of QoL between three months after the cessation of treatment and after the run-in period.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Written informed consent for participation of the study, given before undergoing any study-specific procedures.
-
18-30 years of age (age interval inclusive of both the ends). Both males and females are eligible for the study
-
Clinical diagnose of T1D
-
Five or more years duration of disease
-
HbA1C between 45 and 75 mmol/mol
-
Fasting plasma C-peptide concentration >1.5 pmol/l.
Exclusion Criteria:
-
Inability to provide informed consent
-
Mental incapacity
-
Unwillingness or language barrier precluding adequate understanding or cooperation
-
Ongoing or planned pregnancy within the next 12 months
-
Inadequate or no use of contraceptives
-
Ongoing breast feeding
-
Known sight-threatening retinopathy
-
Creatinine clearance <60 ml/min
-
Life-threatening cardiovascular disease
-
History of drug/alcohol abuse
-
Known or suspected allergy to trial product or related product
-
Recurrent assisted hypoglycemias
-
Taking oral anti-diabetic therapies or any other concomitant medication which may interfere with glucose regulation other than insulin
-
Uncontrolled hypertension (180/105 mmHg or above)
-
History of acute or chronic pancreatitis
-
Personal or family history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)
-
Personal history of non-familial medullary thyroid carcinoma.
-
Any condition that the investigator or sponsor feel would interfere with trial participation or evaluation of results
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Uppsala University Hospital | Uppsala | Sweden | SE-75185 |
Sponsors and Collaborators
- Per-Ola Carlsson
Investigators
- Principal Investigator: Per-Ola Carlsson, MD, PhD, Uppsala University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- U1111-1166-6923